Altre lingue Nexalin Technology, Inc.

Azioni

NXL

US65345B2016

Tempo differito Nasdaq Altri mercati azionari 21:45:08 12/07/2024			Variaz. 5gg	Var. 1 gen.
1,41 ^USD	+1,45%		+9,31%	+248,34%

01/07	Nexalin Technology completa l'offerta di azioni per 5,3 milioni di dollari	MT
28/06	I principali ribassisti di mezzogiorno	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Effect of add-on transcranial alternating current stimulation (tACS) in major depressive disorder: A randomized controlled trial	08/07
Nexalin Technology Completes $5.3 Million Share Offering	01/07
Nexalin Technology Announces Closing of $5.2 Million Public Offering	01/07
Top Midday Decliners	28/06
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	28/06
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	28/06
Top Premarket Decliners	28/06
Nexalin Technology Announces Pricing of $5.2 Million Public Offering	28/06
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal	26/06
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal	26/06
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia	20/06
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency	18/06
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)	13/06
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th	04/06
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device	03/06
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	03/06
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts	22/05
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23	09/05
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	25/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nexalin Technology, Inc.

Azioni

NXL

US65345B2016

Altre lingue

Filtri